

Nanopore-Based Profiling of PEGylation in Nucleic Acid Therapeutics

Gerardo Patiño Guillén,[§] Thieme T. Schmidt,[§] Jeremy J. Baumberg, Jack W. Szostak, Ulrich F. Keyser,^{*} and Filip Bošković^{*}



Cite This: <https://doi.org/10.1021/jacs.6c12398>



Read Online

ACCESS |



Metrics & More




Article Recommendations



Supporting Information

ABSTRACT: Nucleic acid therapeutics (NATs), including aptamers, offer effective strategies for programmable and targeted disease treatment. To improve their stability and circulation time, oligonucleotides are often conjugated to hydrophilic polymers, such as polyethylene glycol (PEG). However, current bulk techniques fail to resolve PEG heterogeneity, especially in complex biological environments. Here, we use nanopore sensing to quantify the PEG conjugation efficiency of the FDA-approved RNA aptamer pegaptanib. We assembled DNA nanostructures that bind pegaptanib, and then we used solid-state nanopores to quantify pegaptanib PEGylation. We further assessed pegaptanib PEGylation and stability in a serum background and demonstrated that nanopore sensing resolves PEG moieties of distinct molecular weights within the oligonucleotide conjugates. Single-molecule profiling of polymer-RNA conjugates enables iterative improvements in oligonucleotide design and provides a direct means to assess their stability in complex biological environments, thereby advancing the development of more effective NATs.



1. INTRODUCTION

Nucleic acid therapeutics (NATs) offer treatment avenues for diverse diseases^{1,2} and include aptamers,³ antisense oligonucleotides,⁴ and mRNA therapeutics,⁵ several of which have already gained FDA approval.⁶ A key barrier to broader clinical adoption remains targeted and efficient delivery to specific organs or tissues.⁷ Successful clinical translation requires delivery systems that enhance stability, promote strong target binding, and facilitate efficient cellular uptake.¹ To address these challenges, a variety of chemical modifications have been introduced to improve NAT stability and pharmacokinetics.⁷ Particularly for shorter RNA therapeutics, PEG conjugation has proven effective, with several PEGylated NATs receiving FDA approval.⁸

PEGylation is the covalent attachment of PEG to nucleic acids at either their 3' or 5' ends.⁹ PEG enhances solubility, reduces aggregation,^{10–12} and prevents renal clearance and nuclease degradation, thereby prolonging the half-life of NATs in the bloodstream.^{13–16} PEGs with molecular weights of 20–40 kDa are commonly used in PEGylated NATs to prolong circulation time by reducing renal clearance.^{8,9} PEGylation is clinically validated for RNA aptamers, including the FDA-approved pegaptanib¹⁷ used to treat neovascular age-related macular degeneration.

However, quantifying PEGylation and PEG's molecular weight distribution remains challenging.^{18–20} Although

chromatographic methods such as HPLC are widely used for high-purity oligonucleotide analysis,²¹ they often suffer from poor resolution due to polymer polydispersity or nonspecific interactions with the stationary phase.¹⁸ Mass spectrometry is similarly limited because PEG's flexible, neutral, and polydisperse structure produces broad, unresolved peaks and suppresses ionization.²² These limitations are amplified in complex mixtures, preventing direct assessment of PEGylated therapeutics in biological environments. Gel electrophoresis offers a semiquantitative tool to assess NAT PEGylation; however, its limited sensitivity and lack of sequence specificity²³ confound quantitative analysis within complex biological backgrounds.

Although reverse transcription polymerase chain reaction (RT-PCR) is a powerful and widely used approach for RNA characterization, it has fundamental limitations for the quantitative analysis of short NATs.^{24,25} Therapeutic small RNAs are often too short for direct RT-PCR because their limited sequence length constrains primer design. Assay

Received: June 17, 2026

Revised: July 17, 2026

Accepted: July 20, 2026



ACS Publications

© XXXX The Authors. Published by
American Chemical Society

A

<https://doi.org/10.1021/jacs.6c12398>
J. Am. Chem. Soc. XXXX, XXX, XXX–XXX




Figure 1. DNA nanostructure-mediated capture of pegaptanib enables PEG characterization by nanopore sensing. (a) Pegaptanib is a PEGylated (5'–40 kDa PEG) RNA aptamer that binds VEGF. (b) PAGE (10% v/v) showing hybridization of PEGylated and non-PEGylated RNA aptamer to DNA oligonucleotides: L–low-range DNA ladder, 1–non-PEGylated RNA aptamer, 2–PEGylated RNA aptamer, 3–non-PEGylated RNA aptamer bound to DNA oligonucleotide (aptamer in excess), and 4–PEGylated RNA aptamer bound to DNA oligonucleotide (aptamer in excess mimicking capture conditions). (c) A 7.2 kbp dsDNA nanostructure captures pegaptanib via hybridization to a complementary DNA overhang. The nanostructure contains three regions with 11 dumbbells each (D), used as reference markers. (d) Nanopore-based sensing of pegaptanib-carrying nanostructure. (e) The translocation of the DNA nanostructure through the nanopore results in a drop in the ionic current. Each reference “D” causes a downward current spike in the ionic current trace. Translocation of pegaptanib bound to the nanostructure produces an additional downward current spike “P”, enabling single-molecule characterization of the drug.

workflows therefore commonly require adapter ligation, tailing, or other template-extension steps prior to amplification.^{24,25} However, these workarounds are incompatible with chemically modified NATs where terminal modifications can prevent adapter ligation, and 2'–OH modifications can impair reverse transcription. Consequently, RT-PCR may be unsuitable for detecting chemically modified short NATs. Beyond detection, RT-PCR also provides no direct measure of PEGylation efficiency.^{26,27} Addition of a radiolabel during pegaptanib synthesis or postsynthetically is an alternative but it is rarely employed due to radiation hazards²⁸ and lack of labeling specificity if tritium is used.²⁹

Accordingly, there is a need for a quantitative method that robustly characterizes PEGylated NATs in complex biological backgrounds. Such a method should enable rapid multiplexed analysis while circumventing interference from chemical modifications, eliminating ligation-associated biases, removing the use of hazardous reagents, and supporting an improved pharmacokinetic evaluation and quality control.

Here, we quantify both the degree of PEGylation and the molecular weight of PEG at the single-molecule level in NATs. Using DNA nanostructure-assisted capture^{23,30} of PEG-RNA conjugates, we characterize PEGylated NATs using nano-

pores,^{31–36} which are compatible with PEG or PEG-containing solutions.^{37–41} The specificity of nanostructure translocation enables quantitative assessment of PEGylation efficiency and multiplexed evaluation of RNA stability in complex backgrounds. Furthermore, we demonstrate that nanopores can resolve PEG molecules of distinct molecular weights within PEG mixtures, revealing polymer heterogeneity and providing a comprehensive characterization of PEGylated NATs. These capabilities establish a solid analytical framework to accelerate the development, optimization, and quality assessment of NATs.

2. RESULTS AND DISCUSSION

2.1. DNA Nanostructure-Assisted Capture Unlocks Nanopore Characterization of PEGylated NATs

First, we establish a strategy that combines the capture of PEGylated NATs into DNA nanostructures for their characterization by nanopore sensing. As a model therapeutic aptamer, we synthesized pegaptanib⁴² (Figure 1a), a 28 nt RNA aptamer of vascular endothelial growth factor (VEGF) (Table S1). We conjugated the 5' end of the aptamer to PEG with a mean molecular weight of 40 kDa via a reaction between the 5'-




Figure 2. Single-molecule quantification of pegaptanib PEGylation via nanopore sensing. (a) We hybridized the PEGylated aptamer to a DNA nanostructure with three consecutive “D” references. Translocation of this construct through a nanopore generated an initial drop in the ionic current, ascribed to the backbone of the nanostructure, followed by three consecutive downward spikes, associated with the three “D” reference structures and a distinct spike “P” ascribed to the 5′–40 kDa PEG RNA aptamer. (b) Non-PEGylated RNA aptamer was hybridized to a DNA nanostructure with two consecutive “D” references and a terminal “D” reference. Translocation of this construct through the same nanopore produced an initial drop in the ionic current associated with the backbone, two consecutive and a terminal downward current spike, associated with the three “D” references, and a small downward current spike “R” ascribed to the RNA aptamer hybridized to the nanostructure’s overhang. (c) We compared the current spike depth of “P” and “R”, which enabled quantitative distinction between PEGylated and non-PEGylated RNA aptamers. The mean normalized spike depth of PEGylated RNA aptamer was 0.55 ± 0.01 , while the mean depth for non-PEGylated RNA aptamer was 0.18 ± 0.01 . Errors represent the standard error of the mean (SEM). (d) We showed the detection of PEGylated pegaptanib in horse serum background. (e) Representative ionic current trace shows baseline stability and high specificity of the translocations in horse serum. (f) We observed a PEGylation efficiency of $\approx 96\%$.

amino-modifier C6 group and *N*-hydroxysuccinimide ester-activated PEG, and we compared it to a commercial standard (Figure S1).

We annealed the RNA aptamer to a reverse-complementary single-stranded DNA (ssDNA) oligonucleotide and performed polyacrylamide gel electrophoresis (PAGE) to demonstrate hybridization to the overhang used for nanostructure-assisted capture (Experimental section, Figure 1b). We hybridized both the non-PEGylated (lane 1) and PEGylated (lane 2) pegaptanib in excess to the complementary DNA oligonucleotide (lanes 3 and 4, respectively), confirming successful hybridization and RNA/DNA duplex formation (Table S2).

After we confirmed the hybridization of pegaptanib to the complementary oligonucleotide, we assembled a DNA nanostructure, which captured pegaptanib with the same complementary oligonucleotide (Figure 1c). The nanostructure featured three successive references “D”, each composed of 11 consecutive DNA dumbbells, which provide nanopore readout selectivity. The “D” regions act as barcode references. Their defined positions create a recognizable current signature that identifies the nanostructure, locates the RNA capture site, and distinguishes analyte-bearing constructs from background

nucleic acids, including genomic DNA contaminants. This also enables multiplexed measurements in a single nanopore experiment⁴³ (Figure S2 and Table S3).

We performed nanopore ionic current measurements using the assembled DNA nanostructure. Upon the application of a voltage across a nanopore separating two chambers filled with an ionic solution, the negatively charged nanostructure, carrying pegaptanib, is driven through the pore toward the positive electrode by electrophoretic force⁴⁴ (Figure 1d). As the nanostructure enters the nanopore, it displaces ions and causes a transient reduction in the ionic current I_0 , which is detected as the DNA nanostructure translocates through the nanopore^{45,46} (Figure 1e). The passage of pegaptanib through the pore induces a larger ion depletion, observed as a distinct secondary downward current spike “P” with a current drop I and charge deficit or area A , enabling single-molecule quantitative detection of pegaptanib. The three references “D” produce a corresponding set of three consecutive downward current spikes, providing a structural fingerprint for the nanostructure³¹ and allowing for a readout suitable for multiplexed characterization.




Figure 3. Pegaptanib degradation profiling in a complex background via nanopore sensing. (a) Experimental workflow in which PEGylated pegaptanib and a 3'-biotinylated RNA of identical sequence are each incubated in horse serum for defined durations, subsequently assembled into nanostructures with distinct nanopore signatures, and measured within the same nanopore for direct comparison of degradation profiles. (b) Intact biotinylated RNA is detected via reaction of the nanostructure with monovalent streptavidin. (c) Produces a pronounced current spike "S" upon translocation that serves as a spike amplification marker. (d) Streptavidin bound to intact biotinylated RNA yielded a mean normalized spike depth of 0.56 ± 0.01 . Following incubation in horse serum at 37°C for (e) 5 min and (f) 24 h, the biotin-modified RNA aptamer displayed a progressively increasing population of translocation events in which streptavidin binding is absent, consistent with RNA degradation.

2.2. Single-Molecule Quantification of Pegaptanib PEGylation

We quantified PEGylation of pegaptanib by simultaneous measurement of two nanostructures with distinct architectures in the same nanopore. The first nanostructure carried PEGylated pegaptanib (Figure 2a), and the second one bound the non-PEGylated aptamer (Figure 2b). To distinguish between the two constructs, the latter nanostructure was designed with two consecutive "D" reference regions at one end and a third "D" reference at the opposite end, generating the distinct downward current spikes during nanopore sensing and a different barcode signature (Figure S2 and Table S4). When the non-PEGylated aptamer passed through the nanopore, it yielded a low-prominence "R" spike attributed to the 28 nt RNA/DNA hybrid between the aptamer and the nanostructure overhang. The distinct nanostructure designs allowed both constructs to translocate through the same nanopore while remaining identifiable from one another, eliminating pore-to-pore variability. This multiplexed measurement yielded two distinct current signatures within a single nanopore; the first was attributed to the nanostructure carrying the PEG-RNA, and the second to the nanostructure carrying the captured RNA, allowing direct comparison of spike observables. Both nanostructures could translocate through

the pore in either the $5' \rightarrow 3'$ or $3' \rightarrow 5'$ directions, with a similar number of events in both orientations, as previously shown⁴⁷ (Figures 2a,b, S3 and S4).

We measured the depth I of the downward current spikes "P" and "R", corresponding to PEGylated and non-PEGylated aptamers, respectively (Figure 2c), and normalized the values to I_0 . The spike depth depends on the nanopore's size and geometry,^{48,49} and variations in the normalized depth values are expected when measurements are performed across different nanopores. The PEGylated aptamer exhibited a mean normalized spike depth I/I_0 of 0.55 ± 0.01 , whereas the non-PEGylated aptamer showed a substantially lower mean value of 0.18 ± 0.01 , allowing for distinction between both aptamer species. We showed that the spike area can also be used to distinguish between the PEGylated and non-PEGylated aptamers (Figure S5). Notably, the normalized depth distribution of "P" indicated a PEGylation level of $\approx 94\%$, which was consistent with our HPLC data (Figure S1). The remaining $\approx 6\%$ corresponded to non-PEGylated aptamers or the translocation of an overhang which did not capture the aptamer. False-positive PEG assignments are unlikely because signals are assigned based on the position of the "D" reference features and nanopore event filtering (Figure S5). Local knotting near the aptamer-binding site could mimic a PEG




Figure 4. Nanopore-based determination of single-PEG polymer molar mass. (a) Native 10% PAGE shows conjugated oligonucleotides to 0 kDa (lane 1), 5 kDa (lane 2), 10 kDa (lane 3), 20 kDa (lane 4), and 40 kDa (lane 5) PEG, and the RNA aptamer conjugated to 40 kDa PEG (pegaptanib, lane 6). Lane L corresponds to a DNA ladder. (b) DNA nanostructures bearing two “D” references and intervening oligonucleotides conjugated to 0, 5, 10, 20, or 40 kDa PEG produce distinct nanopore translocation events, where each PEG-containing oligonucleotide yielded a downward current spike with molecular weight-dependent (c) normalized spike depth and (d) area. (e) In the same nanopore measurement, a nanostructure with a single overhang captures an equimolar mixture of sequence-identical oligonucleotides conjugated to 20 or 40 kDa PEG. (f) Using the mean spike area measured for each pure PEG standard, we assign events in the 20/40 kDa PEG mixture to the corresponding PEG size by Gaussian fitting, thereby quantifying PEG-size heterogeneity in the sample.

signal, but such events are expected to be rare for 7.2 kbp DNA constructs and typically shorter in duration and with higher spike amplitude.^{50,51} Event-to-event variation is minimized by using internal nanostructure features to identify valid events and assigning PEG signals, with aberrant events excluded based on translocation observables and current trace profiling, as demonstrated previously.⁵²

For accurate quantification, the correct design of the nanostructure overhang was essential to prevent steric hindrance by the 40 kDa PEG⁹ and thus enable efficient pegaptanib hybridization (Figure S6). We observed that pegaptanib binds poorly when its PEG-containing 5′ end points toward the nanostructure backbone. In contrast, when PEG is positioned away from the backbone of the nanostructure, pegaptanib shows high hybridization efficiency, as this conformation prevents steric hindrance from PEG and allows for hybridization of the RNA aptamer to the capture overhang, as depicted in Figure 2c.

In a different nanopore measurement, we next used PEGylated pegaptanib in horse serum as a model for monitoring the PEG-aptamer conjugates in a complex environment (Figure 2d). We mixed pegaptanib with serum and incubated the sample with 4 M LiCl and 3.75 M urea at 4 °C for 1 h, to disrupt intermolecular interactions of serum components and to induce the loss of protein structure.^{53–55} After nanostructure assembly and nanopore characterization (Figure 2e), we observed consistent PEGylation efficiency (≈96%), Figure 2f. Raw translocations of the nanostructure and the background are presented in Figure S7. These results demonstrate that the nanostructure design is highly specific and can be used to assess the stability of PEG-based therapeutics within biological backgrounds.

2.3. Nanopore-Based Profiling of Pegaptanib Stability in Complex Backgrounds

Having demonstrated the ability to study NATs in complex biological backgrounds, we next employed nanopore sensing to monitor the stability of PEGylated aptamers in serum over time (Figure 3). The PEGylated aptamer and the unmodified RNA aptamer of identical sequence with a 3' biotin were incubated in horse serum for defined durations, followed by disruption of the serum components by treatment with 4 M LiCl and 3.75 M urea. The two species were then hybridized into structurally distinct nanostructures and measured within the same nanopore, enabling direct comparison of their stability profiles (Figure 3a).

The nanostructure housing the PEGylated aptamer retained the same architecture as described for Figure 2a, consisting of three consecutive reference signals "D" followed by the PEGylated aptamer capture site "P". The biotinylated aptamer was incorporated into a nanostructure flanked by two consecutive "D" references and a terminal "D" reference, allowing unambiguous discrimination between the two constructs (Figure 3b and Table S5). Crucially, conjugation of the biotinylated aptamer nanostructure with monovalent streptavidin gave rise to a sharp current spike "S" during translocation, which amplifies the readout of the intact biotinylated RNA aptamer (Figures 3c and S8) with a mean normalized spike depth of 0.56 ± 0.01 (Figure 3d).

Following incubation in horse serum at 37 °C, the PEGylated aptamer exhibited greater stability than its biotinylated counterpart. For the biotinylated aptamer, the proportion of events retaining streptavidin, which reflects intact RNA, was reduced by $\approx 15\%$ after 5 min of incubation (Figure 3e) and by 98% after 24 h (Figure 3f), indicative of progressive RNA degradation. In contrast, the PEGylated aptamer demonstrated consistent stability across both incubation time points, with $\approx 92\%$ and $\approx 90\%$ of events attributed to the intact aptamer following 5 min and 24 h of incubation, respectively. The superior stability of the PEGylated aptamer is attributed to its chemical modification profile, which includes 2'-fluoro and 2'-O-methyl modifications of the ribose sugar, an inverted deoxythymidine at the 3' end and 5'-PEGylation (Figure S9),^{56,57} in contrast to the 3'-biotinylated RNA aptamer lacking these modifications.

2.4. Determination of Single-PEG Polymer Molecular Weight

We discriminate between PEG moieties of distinct molecular weights conjugated to oligonucleotides. DNA oligonucleotides were conjugated with PEG chains of 5, 10, 20, and 40 kDa using a copper-free click reaction between 3'-dibenzocyclooctyne (DBCO) oligonucleotides and azide-functionalized PEG. Polyacrylamide gel electrophoresis (PAGE) of the PEG-conjugated oligonucleotides is shown in Figure 4a. As expected, increasing PEG molecular weight led to reduced migration rates (lanes 1 to 6; sequences are listed in Table S6).

The PEG-conjugated oligonucleotides were then hybridized to a unique DNA nanostructure via five consecutive complementary overhangs (Figures 4b and S2; sequences are listed in Table S7). The nanostructure featured two "D" references, flanking the polymer attachment sites. During nanopore sensing, an initial ionic current drop corresponded to the translocation of the nanostructure's backbone, followed by downward spikes generated by the "D" references and five additional spikes corresponding to the PEG conjugates. Both

the depth and area of the polymer-associated spikes increased linearly with PEG molecular weight (Figure S10). Incorporation of PEG was further validated through nanopore-based detection using streptavidin binding (Figure S11).

PEG typically exhibits a polydispersity index (PDI) of 1.01 for molecular weights below 5 kDa, increasing to around 1.10 for PEG exceeding 50 kDa.⁵⁸ Variations in chain length affect the polymer's flexibility and effective hydrodynamic volume, both of which influence the resulting ionic current spike depth and area.⁴⁸ Consequently, the inherent polydispersity of PEG introduces additional variability in the measured spike observables. The normalized mean spike depths of 0, 5, 10, 20, and 40 kDa PEG were 0.12 ± 0.01 , 0.18 ± 0.01 , 0.22 ± 0.01 , 0.24 ± 0.01 , and 0.43 ± 0.01 , respectively. The error corresponds to SEM. The difference between molecular weight populations is statistically significant, showing an *f*-ratio value of 224.2 for a Welch's ANOVA test and the *p*-value < 0.00001 (Figure 4c). The spike areas were 4.8 ± 0.1 fC, 6.5 ± 0.1 fC, 7.3 ± 0.2 fC, 9.2 ± 0.3 fC, and 13.2 ± 0.3 fC for 0, 5, 10, 20, and 40 kDa PEG, respectively, further demonstrating that we can distinguish PEG with different molecular weights (Figure 4d). The error corresponds to SEM, the *f*-ratio value was 255.1 for a Welch's ANOVA test and the *p*-value < 0.00001 . The posthoc Games–Howell pairwise comparisons for both observables are included in Table S8. Raw translocations are presented in Figure S12. Nanopores with diameter < 5 nm could be used to increase spatial resolution, allowing for discrimination of minor molecular weight variations and resolving superimposed spike prominence populations, as demonstrated previously.^{34,59} The discrimination of PEG with variable molecular weight is achieved independently of the translocation direction (Figure S13).

In the same nanopore measurement, we included a nanostructure featuring a single capture overhang that binds an equimolar mixture of sequence-identical DNA conjugates carrying either 20 or 40 kDa PEG (Figure 4e). The PEG-dependent spike observables were first established from the reference nanostructure containing pure 20 and 40 kDa PEG conjugates (Figure 4b–d) and further compared in Figure S14. Among the measured observables, spike area provided the clearest separation between the 20 and 40 kDa PEG populations. We therefore used the mean spike areas of the pure 20 and 40 kDa PEG references to fit the mixed-sample distribution with a two-component Gaussian model, with each Gaussian centered on the corresponding PEG molecular weight. This analysis resolved the two PEG populations within the mixture (Figure 4f; raw translocation events are shown in Figure S15). The assignment was further validated by removing the 20 kDa PEG conjugate from the mixture, which eliminated the corresponding spike area population (Figure S16).

The methodology presented demonstrates our ability to characterize oligonucleotide-polymer conjugates at the single-molecule level, enabling profiling of polymer molecular weight distributions and identification of unexpected chain-length variants. This capability supports the correlation of PEGylation profiles with therapeutic performance.

3. CONCLUSIONS

We have introduced a method to quantitatively study polymer-modified oligonucleotides, applying it to measure PEG levels and stability of an FDA-approved RNA aptamer. Our approach enables high-specificity multiplexed quantification of

PEGylated nucleic acids in complex mixtures, such as horse serum, supporting stability assessment of PEG-based therapeutics in biological backgrounds.

The platform provides a single-molecule quantitative tool capable of analyzing PEG-NAT conjugates across a broad range of molecular weights. By relying solely on nucleic acid hybridization, it overcomes enzymatic and ligation biases, removes characterization constraints associated with chemical modifications, offers high sensitivity and specificity, and eliminates the need for hazardous reagents. The DNA nanostructure-assisted approach provides target molecule-specific recognition.²³ In contrast, previous reports focused on the translocation of free PEGs through nanopores and did not provide the target-specific recognition of PEGylated NATs that is required for characterization in relevant complex environments.^{40,60}

Beyond therapeutic monitoring, this approach is well-suited for quality control during drug manufacturing, efficacy testing, assessment of RNA stability, and the rational design of drug delivery systems aimed at improving cellular uptake and pharmacokinetics. Moreover, it provides an opportunity to quantitatively assess molecular weight distribution and single-molecule behavior of polymers with DNA nanostructure-assisted sensing, opening new directions for studying polymer–oligonucleotide conjugates.

4. EXPERIMENTAL SECTION

4.1. Pegaptanib Synthesis

Oligonucleotides were synthesized using a K&A H6 oligonucleotide synthesizer, following optimized solid-phase synthesis protocols.⁴² Standard and modified phosphoramidites, including 2'-F and 2'-OME derivatives, were obtained from Glen Research or ChemGenes. To enable PEGylation, a 5'-amino-modified oligonucleotide was prepared. Subsequent conjugation to a 40 kDa *N*-hydroxysuccinimide (NHS)-activated PEG (purchased from MedChemExpress) was performed under standard coupling conditions and purified with 20% (v/v) prep-scale polyacrylamide-urea gels (National Diagnostics).

4.2. PEG-DNA Conjugates

PEG-DNA conjugates with different molecular weights were purchased from *Biomers*, their sequences are specified in Table S6. Five kDa PEG-DNA were produced upon request; 10 kDa: PEG 10 k (5' modification) mPEG 10 kDa, mPEG 10000; 20 kDa: PEG 20 k (5' modification) mPEG 20 kDa, mPEG 20000; and 40 kDa: PEG 40 k (5' modification) mPEG 40 kDa, mPEG 40000.

4.3. Native Polyacrylamide Gel Electrophoresis (PAGE)

We performed native polyacrylamide gel electrophoresis using Novex TBE Gels, 10% (catalog no. EC62752BOX). The constructs were run with 1 × TriTrack loading dye (Thermo Fisher Scientific, catalog no. R1161), loading 150 to 200 ng of the sample per lane. We applied a constant voltage of 80 V for 90 min. After electrophoresis, we stained the gels in 3 × GelRed buffer (Biotium, catalog no. 41001) and imaged using a GelDoc-It(UVP). Gel images were processed using ImageJ (Fiji).⁶¹

4.4. DNA Nanostructure Assembly

We assembled DNA nanostructures by thermal annealing. We used ssDNA M13mp18 (7249 nt, Guild Biosciences) as scaffold. We first incubated the ssDNA with a 39 nt oligonucleotide complementary to the restriction sites of the enzymes *Bam*HI-HF and *Eco*RI-HF, as reported previously.² We incubated ssDNA (100 nM) with the complementary oligonucleotide (2 μM) in 1 × rCutSmart Buffer (New England Biolabs (NEB)). The annealing was performed at 65 °C with a linear cooling ramp to 25 °C for 40 min. Then, we added to the mixture 1 μL of *Bam*HI-HF (NEB, R3136S) and 1 μL of *Eco*RI-

HF (NEB, R3101S). The reaction mixture was incubated at 37 °C for 1 h and purified using a Monarch PCR and DNA Cleanup Kit (5 μg) (NEB, T1030S), following the manufacturer's instructions. Then, the DNA nanostructure was assembled by mixing the cut ssDNA with the DNA oligonucleotides. The assembly reaction was performed in 10 mM MgCl₂ (Invitrogen, AM9530G) and 10 mM Tris HCl buffer (pH 8.0). All buffers and nuclease-free water (Ambion, catalog no. AM9937) used for assembly were previously filtered in 0.22 μm Millipore syringe filter units (MF-Merck Millipore, catalog no. GSWP04700) and treated with UV light for 10 min. A reaction volume of 40 μL was implemented, which included 800 fmol of the M13 scaffold (20 nM) and a 5-fold excess of DNA oligonucleotides (4 pmol, 100 nM). The target molecule for characterization (pegaptanib or PEG-DNA conjugates) was added in a total 15 times excess (12 pmol, 300 nM). Annealing was performed at 70 °C for 30 s, followed by cooling down over 45 min to room temperature (90 cycles of 30 s with a 0.5 °C drop per cycle). After annealing, we filtered the reaction mixture twice in 100 kDa cutoff Amicon filters, to remove the excess of DNA oligonucleotides. The filtering was performed using 10 mM Tris-HCl (pH 8.0) with 0.5 mM MgCl₂ as buffer.

4.5. Nanopore Fabrication

We produced glass nanopores with diameters ranging from 10 to 15 nm³¹ using a laser-assisted capillary puller (P2000F, Sutter Instruments). The parameters of the puller were HEAT (470–500), VEL (25), DEL (170), and PUL (200). Capillaries were purchased from Sutter Instruments and had an outer diameter of 0.5 mm, an inner diameter of 0.2 mm, and an inner filament. The nanopores were put into a PDMS device to facilitate measurements as described previously.⁵² We performed IV curves in 4 M LiCl for each nanopore produced (Table S9).

4.6. Nanopore Measurements

We characterized the DNA nanostructures with nanopores. Sensing was conducted with an Axopatch 200B amplifier (Molecular Devices) in a solution containing 4 M LiCl, 1× Tris-EDTA (TE) buffer, pH 9.4. A measuring potential of 600 mV was used for translocation of the nanostructures. The amplifier had a 100 kHz internal filter, and we used an eight-pole analog low-pass Bessel filter (900CT, Frequency Devices) with a cutoff frequency of 50 kHz to filter the output signal. The data were acquired using a sampling frequency of 1 MHz in a PCI-6251 data card (National Instruments). We used custom LabVIEW code to identify individual translocation events in the ionic current recordings. We also used custom LabVIEW code to filter out translocation events based on duration, current drop, and charge deficit. Nonspecific translocations and drops in the ionic current were effectively removed by referencing the mean event current of the DNA nanostructure. Translocation event selection was further refined by specifying ranges of event duration and charge deficit. Unfolded translocations, where the features of the design were depicted, were selected for peak analysis. For peak characterization, we computed the spike depth and area, which enabled assessment of PEGylation and PEG molecular weight.

4.7. DNA Nanostructure Assembly and Characterization with Horse Serum Background

First, 0.5 μL of horse serum (Gibco, catalog no. 16050-130) was mixed with 2 μL of 100 μM pegaptanib (200 pmol) for incubation periods of 0 min, 5 min, and 24 h at 37 °C. The mixture was diluted in 10 μL of 8 M LiCl and 7.5 μL of 10 M urea. The 20 μL mixture, holding horse serum, 10 μM pegaptanib, 4 M LiCl, and 3.75 M urea, was incubated for 1 h at 4 °C. The nanostructure assembly was performed in a 20 μL reaction volume containing 10 mM Tris HCl buffer (pH 8.0), 400 fmol of the M13 scaffold (20 nM), and a 5-fold excess of DNA oligonucleotides (4 pmol, 100 nM). Also, 1.2 μL of serum-pegaptanib-LiCl-urea mixture was added to have a 15-fold pegaptanib excess (12 pmol, 300 nM), 240 mM LiCl, and 225 mM urea. Annealing was performed at 70 °C for 30 s, followed by cooling down over 45 min to room temperature (90 cycles of 30 s with a 0.5 °C drop per cycle). After annealing, we filtered the reaction mixture

twice in 100 kDa cutoff Amicon filters to remove excess DNA oligonucleotides. The filtering was performed using 10 mM Tris–HCl (pH 8.0) with 0.5 mM MgCl₂ as a buffer exchange. For nanopore measurements, the sample was diluted to 200 pM in 4 M LiCl.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/jacs.6c12398>.

Nanostructure designs, supplementary schematics, raw ionic current traces, supporting nanopore experiments, IV curves, and the sequences of DNA oligonucleotides and RNA used for nanostructure assembly and target analysis (PDF)

■ AUTHOR INFORMATION

Corresponding Authors

Ulrich F. Keyser – Cavendish Laboratory, University of Cambridge, Cambridge CB3 0HE, U.K.; Email: ufk20@cam.ac.uk

Filip Bošković – Howard Hughes Medical Institute, Department of Chemistry, The University of Chicago, Chicago, Illinois 60637, United States; orcid.org/0000-0001-7663-2408; Email: filipboskovic@uchicago.edu

Authors

Gerardo Patiño Guillén – Cavendish Laboratory, University of Cambridge, Cambridge CB3 0HE, U.K.; orcid.org/0009-0000-5742-7601

Thieme T. Schmidt – Cavendish Laboratory, University of Cambridge, Cambridge CB3 0HE, U.K.; orcid.org/0000-0002-6802-3036

Jeremy J. Baumberg – Cavendish Laboratory, University of Cambridge, Cambridge CB3 0HE, U.K.; orcid.org/0000-0002-9606-9488

Jack W. Szostak – Howard Hughes Medical Institute, Department of Chemistry, The University of Chicago, Chicago, Illinois 60637, United States; orcid.org/0000-0003-4131-1203

Complete contact information is available at: <https://pubs.acs.org/10.1021/jacs.6c12398>

Author Contributions

§G.P.G. and T.T.S. contributed equally. The manuscript was written through the contributions of all authors. All authors have given their approval to the final version of the manuscript.

Notes

The authors declare the following competing financial interest(s): F.B. and U.F.K. are inventors of two patents related to RNA characterization with nanopores (UK patent application no. 2113935.7, in process; UK patent application nos. 2112088.6 and PCT/GB2022/052171, in process) submitted by Cambridge Enterprise on behalf of the University of Cambridge. U.F.K. is a co-founder of Cambridge Nucleomics. The remaining authors declare no competing interests.

■ ACKNOWLEDGMENTS

G.P.G. is supported by the Engineering and Physical Sciences Research Council (EPSRC) additional funding award for Postdoctoral Pathway Fellowships (UKRI3035), the EPSRC

CDT MRes/Ph.D. Studentship in Nanoscience and Nanotechnology (NanoDTC Cambridge EP/S022953/1), and the Trinity-Henry Barlow Scholarship. T.T.S. acknowledges UK EPSRC grant EP/X037770/1 and the European Research Council (ERC) under the Horizon2020 Research and Innovation Program PICOFORCE (883703). J.W.S. is an investigator of the Howard Hughes Medical Institute (HHMI). F.B. acknowledges funding from HHMI and the European Molecular Biology Organization through a Long-Term Fellowship (ALTF 106–2023). U.F.K. acknowledges funding from UK Research and Innovation (UKRI) under the UK government's Horizon Europe funding guarantee EP/X023311/1, an ERC consolidator grant (DesignerPores no. 647144), an ERC-2019-PoC grant (PoreDetect no. 899538), and the European Union under the Horizon2020 Program, FET-Open: DNA-FAIRYLIGHTS, Grant Agreement No. 964995. J.J.B. acknowledges funding from EPSRC grants EP/X037770/1, EP/Y008162/1, and EP/Y036379/1 and from the ERC grant PICOFORCE 883703. We acknowledge Prof. Casey M. Platnich for insightful discussions.

■ REFERENCES

- (1) Kulkarni, J. A.; Witzigmann, D.; Thomson, S. B.; Chen, S.; Leavitt, B. R.; Cullis, P. R.; van der Meel, R. The Current Landscape of Nucleic Acid Therapeutics. *Nat. Nanotechnol.* **2021**, *16* (6), 630–643.
- (2) Liu, C.; Shi, Q.; Huang, X.; Koo, S.; Kong, N.; Tao, W. mRNA-Based Cancer Therapeutics. *Nat. Rev. Cancer* **2023**, *23* (8), 526–543.
- (3) Zhu, L.; Yang, J.; Ma, Y.; Zhu, X.; Zhang, C. Aptamers Entirely Built from Therapeutic Nucleoside Analogues for Targeted Cancer Therapy. *J. Am. Chem. Soc.* **2022**, *144* (4), 1493–1497.
- (4) Knerr, L.; Prakash, T. P.; Lee, R.; Drury, W. J.; Nikan, M.; Fu, W.; Pirie, E.; Maria, L. De; Valeur, E.; Hayen, A.; Ölwegård-Halvarsson, M.; Broddedfalk, J.; Ämmälä, C.; Østergaard, M. E.; Mueller, J.; Sundström, L.; Andersson, P.; Janzén, D.; Jansson-Löfmark, R.; Seth, P. P.; Andersson, S. Glucagon like Peptide 1 Receptor Agonists for Targeted Delivery of Antisense Oligonucleotides to Pancreatic Beta Cell. *J. Am. Chem. Soc.* **2021**, *143* (9), 3416–3429.
- (5) Ma, Y.; Fenton, O. S. A Unified Strategy to Improve Lipid Nanoparticle Mediated mRNA Delivery Using Adenosine Triphosphate. *J. Am. Chem. Soc.* **2023**, *145* (36), 19800–19811.
- (6) Zhu, Y.; Zhu, L.; Wang, X.; Jin, H. RNA-Based Therapeutics: An Overview and Prospectus. *Cell Death & Dis* **2022**, *13* (7), 1–15.
- (7) Roberts, T. C.; Langer, R.; Wood, M. J. A. Advances in Oligonucleotide Drug Delivery. *Nat. Rev. Drug Discovery* **2020**, *19* (10), 673–694.
- (8) Gao, Y.; Joshi, M.; Zhao, Z.; Mitragotri, S. PEGylated Therapeutics in the Clinic. *Bioeng. Transl. Med.* **2024**, *9* (1), No. e10600.
- (9) Ikeda, Y.; Nagasaki, Y. Impacts of PEGylation on the Gene and Oligonucleotide Delivery System. *J. Appl. Polym. Sci.* **2014**, *131* (9), app.40293.
- (10) Yoshinaga, N.; Naito, M.; Tachihara, Y.; Boonstra, E.; Osada, K.; Cabral, H.; Uchida, S. PEGylation of mRNA by Hybridization of Complementary PEG-RNA Oligonucleotides Stabilizes mRNA without Using Cationic Materials. *Pharmaceutics* **2021**, *13* (6), 800.
- (11) Lu, X.; Zhang, K. PEGylation of Therapeutic Oligonucleotides: From Linear to Highly Branched PEG Architectures. *Nano Res.* **2018**, *11* (10), 5519.
- (12) Mishra, S.; Webster, P.; Davis, M. E. PEGylation Significantly Affects Cellular Uptake and Intracellular Trafficking of Non-Viral Gene Delivery Particles. *Eur. J. Cell Biol.* **2004**, *83* (3), 97–111.
- (13) Batra, J.; Robinson, J.; Mehner, C.; Hockla, A.; Miller, E.; Radisky, D. C.; Radisky, E. S. PEGylation Extends Circulation Half-Life While Preserving In Vitro and In Vivo Activity of Tissue Inhibitor

of Metalloproteinases-1 (TIMP-1). *PLoS One* **2012**, *7* (11), No. e50028.

(14) Chen, B. M.; Cheng, T. L.; Roffler, S. R. Polyethylene Glycol Immunogenicity: Theoretical, Clinical, and Practical Aspects of Anti-Polyethylene Glycol Antibodies. *ACS Nano* **2021**, *15* (9), 14022–14048.

(15) Pelaz, B.; Del Pino, P.; Maffre, P.; Hartmann, R.; Gallego, M.; Rivera-Fernández, S.; De La Fuente, J. M.; Nienhaus, G. U.; Parak, W. J. Surface Functionalization of Nanoparticles with Polyethylene Glycol: Effects on Protein Adsorption and Cellular Uptake. *ACS Nano* **2015**, *9* (7), 6996–7008.

(16) Shokrzadeh, N.; Winkler, A. M.; Dirin, M.; Winkler, J. Oligonucleotides Conjugated with Short Chemically Defined Polyethylene Glycol Chains Are Efficient Antisense Agents. *Bioorg. Med. Chem. Lett.* **2014**, *24* (24), 5758.

(17) Gabrielle, P. H.; Mehta, H.; Barthelmes, D.; Daien, V.; Nguyen, V.; Gillies, M. C.; Creuzot-Garcher, C. P. From Randomised Controlled Trials to Real-World Data: Clinical Evidence to Guide Management of Diabetic Macular Oedema. *Prog. Retin. Eye Res.* **2023**, *97*, 101219.

(18) Su, Y. C.; Chen, B. M.; Chuang, K. H.; Cheng, T. L.; Roffler, S. R. Sensitive Quantification of PEGylated Compounds by Second-Generation Anti-Poly(Ethylene Glycol) Monoclonal Antibodies. *Bioconjugate Chem.* **2010**, *21* (7), 1264–1270.

(19) Gong, J.; Gu, X.; Achanzar, W. E.; Chadwick, K. D.; Gan, J.; Brock, B. J.; Kishnani, N. S.; Humphreys, W. G.; Iyer, R. A. Quantitative Analysis of Polyethylene Glycol (PEG) and PEGylated Proteins in Animal Tissues by LC-MS/MS Coupled with in-Source CID. *Anal. Chem.* **2014**, *86* (15), 7642–7649.

(20) Cheng, T. L.; Chuang, K. H.; Chen, B. M.; Roffler, S. R. Analytical Measurement of Pegylated Molecules. *Bioconjugate Chem.* **2012**, *23* (5), 881–899.

(21) Hannauer, F.; Black, R.; Ray, A. D.; Stulz, E.; Langley, G. J.; Holman, S. W. Advancements in the Characterisation of Oligonucleotides by High Performance Liquid Chromatography-Mass Spectrometry in 2021: A Short Review. *Anal. Sci. Adv.* **2022**, *3* (3–4), 90–102.

(22) Bento, C.; Katz, M.; Santos, M. M. M.; Afonso, C. A. M. Striving for Uniformity: A Review on Advances and Challenges To Achieve Uniform Polyethylene Glycol. *Org. Process Res. Dev.* **2024**, *28* (4), 860–890.

(23) Bošković, F.; Zhu, J.; Tivony, R.; Ohmann, A.; Chen, K.; Alawami, M. F.; Đorđević, M.; Ermann, N.; Pereira Dias, J.; Fairhead, M.; Howarth, M.; Baker, S.; Keyser, U. F. Simultaneous Identification of Viruses and SARS-CoV-2 Variants with Programmable DNA Nanobait. *Nat. Nanotechnol.* **2023**, *18*, 290–298.

(24) Chimento, D. P.; Anderson, A. L.; Fial, I.; Ascoli, C. A. Bioanalytical Assays for Oligonucleotide Therapeutics: Adding Antibody-Based Immunoassays to the Toolbox as an Orthogonal Approach to LC-MS/MS and Ligand Binding Assays. *Nucleic Acid Ther.* **2025**, *35* (1), 6–15.

(25) Bost, J. P.; Barriga, H.; Holme, M. N.; Gallud, A.; Maugeri, M.; Gupta, D.; Lehto, T.; Valadi, H.; Esbjörner, E. K.; Stevens, M. M.; El-Andaloussi, S. Correction to Delivery of Oligonucleotide Therapeutics: Chemical Modifications, Lipid Nanoparticles, and Extracellular Vesicles. *ACS Nano* **2021**, *15* (11), 18590–18591.

(26) Czauderna, F.; Fechtner, M.; Dames, S.; Aygün, H.; Klippel, A.; Pronk, G. J.; Giese, K.; Kaufmann, J. Structural Variations and Stabilising Modifications of Synthetic SiRNAs in Mammalian Cells. *Nucleic Acids Res.* **2003**, *31* (11), 2705–2716.

(27) Decombe, A.; Peersen, O.; Sutto-Ortiz, P.; Chamontin, C.; Piorkowski, G.; Canard, B.; Nisole, S.; Decroly, E. Internal RNA 2'-O-Methylation on the HIV-1 Genome Impairs Reverse Transcription. *Nucleic Acids Res.* **2024**, *52* (3), 1359–1373.

(28) Kopf, S.; Bourriquen, F.; Li, W.; Neumann, H.; Junge, K.; Beller, M. Recent Developments for the Deuterium and Tritium Labeling of Organic Molecules. *Chem. Rev.* **2022**, *122* (6), 6634–6718.

(29) Berman, C. L.; Antonsson, M.; Batkai, S.; Bosgra, S.; Chopda, G. R.; Driessen, W.; Foy, J.; Hassan, C.; Hu, X. S.; Jang, H. G.;

Meena; Sanseverino, M.; Thum, T.; Wang, Y.; Wild, M.; Wu, J. T. OSWG Recommended Approaches to the Nonclinical Pharmacokinetic (ADME) Characterization of Therapeutic Oligonucleotides. *Nucleic Acid Ther.* **2023**, *33* (5), 287–305.

(30) Li, Y.; Wang, Y.; Yu, C.; Hou, S.; Mylona, E.; Naydenova, P.; Zhao, J.; Yuan, H.; Duan, J.; Runge, H. F. P.; Baker, S.; Zhu, J.; Keyser, U. F. DNA Nanoarray for Multiplexed RNA Detection With Single-Molecule Readout. *Adv. Sci.* **2026**, *13*, No. e75319.

(31) Bell, N. A. W.; Keyser, U. F. Digitally Encoded DNA Nanostructures for Multiplexed, Single-Molecule Protein Sensing with Nanopores. *Nat. Nanotechnol.* **2016**, *11* (7), 645–651.

(32) Bošković, F.; Maffeo, C.; Patiño-Guillén, G.; Tivony, R.; Aksimentiev, A.; Keyser, U. F. Nanopore Translocation Reveals Electrophoretic Force on Noncanonical RNA:DNA Double Helix. *ACS Nano* **2024**, *18* (23), 15013–15024.

(33) Mensing, P.; Charron, M.; Bouhamidi, M. Y.; Tabard-Cossa, V. Folding Dynamics of Linear SsDNA-DsDNA Heterostructures through Solid-State Nanopores. *Macromolecules* **2025**, *58*, 4094.

(34) Liu, K.; Pan, C.; Kuhn, A.; Nievergelt, A. P.; Fantner, G. E.; Milenkovic, O.; Radenovic, A. Detecting Topological Variations of DNA at Single-Molecule Level. *Nat. Commun.* **2019**, *10* (1), 1–9.

(35) Lin, C. Y.; Fotis, R.; Xia, Z.; Kavetsky, K.; Chou, Y. C.; Niedzwiecki, D. J.; Biondi, M.; Thei, F.; Drndić, M. Ultrafast Polymer Dynamics through a Nanopore. *Nano Lett.* **2022**, *22* (21), 8719–8727.

(36) Steinbock, L. J.; Krishnan, S.; Bulushev, R. D.; Borgeaud, S.; Blokesch, M.; Feletti, L.; Radenovic, A. Probing the Size of Proteins with Glass Nanopores. *Nanoscale* **2014**, *6* (23), 14380–14387.

(37) Chau, C.; Marcuccio, F.; Soulias, D.; Edwards, M. A.; Tuplin, A.; Radford, S. E.; Hewitt, E.; Actis, P. Probing RNA Conformations Using a Polymer-Electrolyte Solid-State Nanopore. *ACS Nano* **2022**, *16* (12), 20075–20085.

(38) Zheng, F.; Li, H. L.; Yang, J.; Wang, H.; Qin, G.; Chen, D.; Sha, J. Improving Macromolecule Crowding Configurations in Nanopores for Protein Sensing. *Chem. Commun.* **2024**, *60* (95), 14097–14100.

(39) Piguet, F.; Ouldali, H.; Discala, F.; Breton, M. F.; Behrends, J. C.; Pelta, J.; Oukhaled, A. High Temperature Extends the Range of Size Discrimination of Nonionic Polymers by a Biological Nanopore. *Sci. Rep.* **2016**, *6* (1), 1–10.

(40) Robertson, J. W. F.; Rodrigues, C. G.; Stanford, V. M.; Robinson, K. A.; Krasilnikov, O. V.; Kasianowicz, J. J. Single-Molecule Mass Spectrometry in Solution Using a Solitary Nanopore. *Proc. Natl. Acad. Sci. U. S. A.* **2007**, *104* (20), 8207–8211.

(41) Kumar, S.; Tao, C.; Chien, M.; Hellner, B.; Balijepalli, A.; Robertson, J. W. F.; Li, Z.; Russo, J. J.; Reiner, J. E.; Kasianowicz, J. J.; Ju, J. PEG-Labeled Nucleotides and Nanopore Detection for Single Molecule DNasequencing by Synthesis. *Sci. Rep.* **2012**, *2* (1), 684.

(42) Boskovic, F.; Gupta, P. D.; Zhang, J.; Krishnan, Y.; Szostak, J. W. A Nucleic Acid Labeling Chemistry Reveals Surface DNA on Exosomes. *bioRxiv* **2025**, *11* (18), 689134.

(43) Patiño-Guillén, G.; Pešović, J.; Panić, M.; Earle, M.; Ninković, A.; Petrușca, S.; Savić-Pavićević, D.; Keyser, U. F.; Bošković, F. Quantification of Disease-Associated RNA Tandem Repeats by Nanopore Sensing. *Nat. Commun.* **2026**, *17*, 6219.

(44) Xue, L.; Yamazaki, H.; Ren, R.; Wanunu, M.; Ivanov, A. P.; Edel, J. B. Solid-State Nanopore Sensors. *Nat. Rev. Mater.* **2020**, *5* (12), 931–951.

(45) Kumar Sharma, R.; Agrawal, I.; Dai, L.; Doyle, P. S.; Garaj, S. Complex DNA Knots Detected with a Nanopore Sensor. *Nat. Commun.* **2019**, *10* (1), 4473.

(46) Roelen, Z.; Tabard-Cossa, V. Synthesis of Length-Tunable DNA Carriers for Nanopore Sensing. *PLoS One* **2023**, *18* (8), No. e0290559.

(47) Seth, S.; Bhattacharya, A. How Capture Affects Polymer Translocation in a Solitary Nanopore. *J. Chem. Phys.* **2022**, *156* (24), 244902.

(48) Li, Y.; Sandler, S. E.; Keyser, U. F.; Zhu, J. DNA Volume, Topology, and Flexibility Dictate Nanopore Current Signals. *Nano Lett.* **2023**, *23* (15), 7054–7061.

- (49) Charron, M.; Roelen, Z.; Wadhwa, D.; Tabard-Cossa, V. Improved Conductance Blockage Modeling of Cylindrical Nanopores, from 2D to Thick Membranes. *Nano Lett.* **2024**, *24* (34), 10527–10533.
- (50) Plesa, C.; Verschuere, D.; Pud, S.; Van Der Torre, J.; Ruitenber, J. W.; Witteveen, M. J.; Jonsson, M. P.; Grosberg, A. Y.; Rabin, Y.; Dekker, C. Direct Observation of DNA Knots Using a Solid-State Nanopore. *Nat. Nanotechnol.* **2016**, *11* (12), 1093–1097.
- (51) Zheng, F.; Suma, A.; Maffeo, C.; Chen, K.; Alawami, M.; Sha, J.; Aksimentiev, A.; Micheletti, C.; Keyser, U. F. Torsion-Driven Plectoneme Formation During Nanopore Translocation of DNA Polymers. *PRX* **2025**, *15* (3), 031041.
- (52) Patiño-Guillén, G.; Pešović, J.; Panić, M.; Savić-Pavićević, D.; Bošković, F.; Keyser, U. F. Single-Molecule RNA Sizing Enables Quantitative Analysis of Alternative Transcription Termination. *Nat. Commun.* **2024**, *15* (1), 1–12.
- (53) Sinha, R.; Khare, S. K. Protective Role of Salt in Catalysis and Maintaining Structure of Halophilic Proteins against Denaturation. *Front. Microbiol.* **2014**, *5* (APR), 80043.
- (54) Madani, M.; Hamacher, T.; Platten, F. Urea and Salt Induced Modulation of Protein Interactions: Implications for Crystallization and Liquid–Liquid Phase Separation. *Soft Matter* **2025**, *21* (10), 1937–1948.
- (55) Platnich, C. M.; Earle, M. K.; Keyser, U. F. Chemical Annealing Restructures RNA for Nanopore Detection. *J. Am. Chem. Soc.* **2024**, *146* (19), 12919–12924.
- (56) Green, L. S.; Jellinek, D.; Bell, C.; Beebe, L. A.; Feistner, B. D.; Gill, S. C.; Jucker, F. M.; Janjić, N. Nuclease-Resistant Nucleic Acid Ligands to Vascular Permeability Factor/Vascular Endothelial Growth Factor. *Chem. Biol.* **1995**, *2* (10), 683–695.
- (57) Zhou, J.; Rossi, J. Aptamers as Targeted Therapeutics: Current Potential and Challenges. *Nat. Rev. Drug Discovery* **2017**, *16* (3), 181–202.
- (58) Gaballa, S. A.; Naguib, Y.; Mady, F. M.; Khaled, K. A. Polyethylene Glycol: Properties, Applications, and Challenges. *J. Adv. Biomedical Pharm. Sci.* **2023**, *0* (0), 26–36.
- (59) Chen, X.; Liu, Y.; Zhang, F.; Li, A.; Li, Y.; Ji, R.; Hu, R.; Sun, X.; Chen, K. Breaking the Size Barrier in Glass Nanopores to 2 Nm: A Path to High-Resolution Biomolecular Fingerprinting. *Small* **2026**, *22*, No. e73779.
- (60) Chen, K.; Li, M.; Muthukumar, M. Electrophoretic Translocation of Star-Shaped Polymers through Single Solid-State Nanopores. *Macromol* **2024**, *57* (14), 6693–6704.
- (61) Schindelin, J.; et al. Fiji: an open-source platform for biological-image analysis. *Nat. Methods* **2012**, *9* (7), 676–682.